Basiliximab induction versus no induction in adult heart transplantation
Clinical Transplantation · 2023
DOI: 10.1111/ctr.14937 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2023. Verfasst von Katelyn N Rudzik und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Heart Transplantation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Background
Induction immunosuppression in heart transplant recipients varies greatly by center. Basiliximab (BAS) is the most commonly used induction immunosuppressant but has not been shown to reduce rejection or improve survival. The objective of this retrospective study was to compare rejection, infection, and mortality within the first 12 months following heart transplant in patients who received BAS or no induction.
Methods
This was a retrospective cohort study of adult heart transplant recipients given BAS or no induction from January 1, 2017 to May 31, 2021. The primary endpoint was incidence of treated acute cellular rejection (ACR) at 12‐months post‐transplant. Secondary endpoints included ACR at 90 days post‐transplant, incidence of antibody‐mediated rejection (AMR) at 90 days and 1 year, incidence of infection, and all‐cause mortality at 1 year.
Results
A total of 108 patients received BAS, and 26 patients received no induction within the specified timeframe. There was a lower incidence of ACR within the first year in the BAS group compared to the no induction group (27.7 vs. 68.2%, p < .002). BAS was independently associated with a lower probability of having a rejection event during the first 12‐months post‐transplant (hazard ratio (HR) .285, 95% confidence interval [CI] .142–.571, p < .001). There was no difference in the rate of infection and in mortality after hospital discharge at 1‐year post‐transplant (6% vs. 0%, p = .20).
Conclusion
BAS appears to be associated with greater freedom from rejection without an increase in infections. BAS may be a preferred to a no induction strategy in patients undergoing heart transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
- Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
- Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Edward T Horn
Zitieren
APA
Rudzik, K. N., Rivosecchi, R. M., Palmer, B. A., Hickey, G. W., Huston, J. H., Keebler, M. E., Kaczorowski, D. J., & Horn, E. T. (2023). Basiliximab induction versus no induction in adult heart transplantation. Clinical Transplantation. https://doi.org/10.1111/ctr.14937
Vancouver
Rudzik KN, Rivosecchi RM, Palmer BA, Hickey GW, Huston JH, Keebler ME, et al. Basiliximab induction versus no induction in adult heart transplantation. Clinical Transplantation. 2023. doi:10.1111/ctr.14937
BibTeX
@article{Rudzik2023,
author = {Rudzik, Katelyn N and Rivosecchi, Ryan M and Palmer, Brittany A and Hickey, Gavin W and Huston, Jessica H and Keebler, Mary E and Kaczorowski, David J and Horn, Edward T},
title = {Basiliximab induction versus no induction in adult heart transplantation},
journal = {Clinical Transplantation},
year = {2023},
doi = {10.1111/ctr.14937}
}
EUVIMED